Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1095

Shown on this page

Current sort

Stored official records

Conditions: Adamantinomatous Craniopharyngioma, Cancer, Colorectal Cancer, Desmoid, Endometrial Carcinoma, Familial Adenomatous Polyposis (FAP), HCC, Locally Advanced Solid Tumor, Metastatic Cancer, Metastatic Castration-resistant Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Prostate Cancer, Solid Tumor, WNT Pathway
Interventions: Bevacizumab, FOG-001, Nivolumab, Trifluridine/tipiracil, mFOLFOX-6; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Dexamethasone, Elotuzumab, Linvoseltamab, Pomalidomide; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more

Conditions: Breast Adenocarcinoma, Cervical Cancer, Endometrial Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Fallopian Tube Cancer, High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Mesothelioma, Non-small Cell Lung Cancer, Platinum Sensitive Ovarian Cancer (PSOC), Platinum-resistant Ovarian Cancer (PROC), Primary Peritoneal Carcinoma, Primary Refractory Ovarian Cancer, Triple Negative Breast Cancer, Uterine Cancer
Interventions: Bevacizumab, Carboplatin, Erythromycin, Itraconazole, Pembrolizumab, Rina-S; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Premature
Interventions: Enfamil® DHA & ARA Supplement for Special Dietary Use; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Up to 36 Weeks
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Acetaminophen (or equivalent), Antihistamine, Dexamethasone (or equivalent), H2 Receptor Antagonist, Irinotecan, Lenvatinib, MK-4830, Paclitaxel, Pembrolizumab, Sacituzumab tirumotecan, Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Teclistamab; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Interventions: Elenestinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more

Conditions: Amyotrophic Lateral Sclerosis, Behavioral Variant Frontotemporal Dementia (bvFTD), C9orf72, Corticobasal Degeneration (CBD), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Frontotemporal Lobar Degeneration (FTLD), GRN Related Frontotemporal Dementia, MAPT Gene Mutation, Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic PSP (oPSP), Oligosymptomatic Progressive Supranuclear Palsy, Progressive Supranuclear Palsy (PSP), Semantic Variant Primary Progressive Aphasia (svPPA), TBK1 Gene Mutation
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more

Conditions: Follicular Lymphoma, Lymphoma, Diffuse Large B-Cell, Lymphoma, Non-Hodgkin's
Interventions: LY4584180, Rituximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Atopic Dermatitis
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • Alpharetta, Georgia + 3 more

Conditions: Parkinson's Disease
Interventions: Placebo, Prasinezumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours); Drug
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more

About this UCLA Health institution page

What this page lists: ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCLA Health

Filter and sort this campus

Stored official records

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

About this UCLA Health institution page